Amphastar Pharmaceuticals (AMPH) Financials

$23.50 -0.92 (-3.77%)

Closing price 04:00 PM Eastern

Extended Trading

$25.55 +2.05 (+8.72%)

As of 06:18 PM Eastern

Annual Income Statements for Amphastar Pharmaceuticals

This table shows Amphastar Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-11	-2.79	9.82	3.65	-5.74	49	1.40	62	91	138	160
Consolidated Net Income / (Loss)	-11	-2.79	9.82	3.65	-6.66	47	1.10	63	91	138	160
Net Income / (Loss) Continuing Operations	-11	-2.79	9.82	3.65	-6.66	47	1.10	63	91	138	160
Total Pre-Tax Income	-18	-10	15	1.25	-9.93	60	4.64	84	116	171	190
Total Operating Income	-18	-6.90	15	-1.27	-8.62	-0.04	11	70	107	197	205
Total Gross Profit	51	77	104	91	107	132	143	200	249	351	374
Total Revenue	210	252	255	240	295	322	350	438	499	644	732
Operating Revenue	210	252	255	240	295	322	350	438	499	644	732
Total Cost of Revenue	159	174	151	150	188	190	207	238	250	293	358
Operating Cost of Revenue	159	174	151	150	188	190	207	238	250	293	358
Total Operating Expenses	69	84	89	92	116	132	132	130	141	154	168
Selling, General & Admin Expense	35	42	42	44	50	50	50	51	45	52	57
Marketing Expense	5.56	5.47	5.47	6.46	8.16	13	15	17	22	29	38
Research & Development Expense	29	37	42	44	58	69	67	61	75	74	74
Total Other Income / (Expense), net	-0.17	-3.47	-0.75	2.52	-1.30	60	-6.32	14	8.54	-26	-16
Interest Expense	0.61	0.99	1.02	0.83	0.24	0.12	0.37	0.89	1.85	27	30
Interest & Investment Income	0.24	0.32	0.27	0.43	0.46	1.00	0.64	0.60	1.32	5.46	11
Other Income / (Expense), net	0.20	-2.79	0.01	2.92	-1.52	59	-6.59	15	9.07	-3.93	4.08
Income Tax Expense	-7.45	-7.58	4.81	-2.40	-3.27	14	3.54	21	23	32	30
Other Gains / (Losses), net	-	-	-	-	-	-	0.00	-0.21	-1.18	-1.98	-0.57
Basic Earnings per Share	($0.25)	($0.06)	$0.22	$0.08	($0.12)	$1.04	$0.03	$1.30	$1.88	$2.85	$3.29
Weighted Average Basic Shares Outstanding	41.96M	44.96M	45.38M	46.11M	46.40M	46.98M	47.04M	47.78M	48.55M	48.27M	48.43M
Diluted Earnings per Share	($0.25)	($0.06)	$0.21	$0.08	($0.12)	$0.98	$0.03	$1.25	$1.74	$2.60	$3.06
Weighted Average Diluted Shares Outstanding	41.96M	44.96M	47.50M	48.37M	46.40M	49.91M	49.12M	49.78M	52.43M	53.00M	52.06M
Weighted Average Basic & Diluted Shares Outstanding	42.80M	46.50M	45.80M	45.60M	46.79M	46.24M	47.43M	48.15M	47.90M	48.10M	47.65M

This table shows Amphastar Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	16	34	26	26	49	36	43	38	40	38
Consolidated Net Income / (Loss)	16	34	26	26	49	36	43	38	40	38
Net Income / (Loss) Continuing Operations	16	34	26	26	49	36	43	38	40	38
Total Pre-Tax Income	23	41	34	33	64	41	48	50	48	44
Total Operating Income	23	38	33	37	73	54	48	55	57	45
Total Gross Profit	59	71	74	73	108	96	90	95	102	87
Total Revenue	120	135	140	146	181	178	172	182	191	187
Operating Revenue	120	135	140	146	181	178	172	182	191	187
Total Cost of Revenue	62	64	66	73	72	82	82	87	89	100
Operating Cost of Revenue	62	64	66	73	72	82	82	87	89	100
Total Operating Expenses	35	33	40	36	36	42	42	40	45	42
Selling, General & Admin Expense	12	11	13	12	13	13	16	13	15	13
Marketing Expense	4.78	5.47	7.11	6.72	6.41	8.62	9.37	9.01	9.00	10
Research & Development Expense	19	17	20	17	17	20	17	18	21	18
Total Other Income / (Expense), net	-0.63	3.43	0.14	-4.09	-9.04	-13	-0.13	-4.97	-9.37	-1.18
Interest Expense	0.57	0.53	0.40	3.60	14	9.46	8.61	8.61	6.70	6.43
Interest & Investment Income	0.33	0.58	0.92	1.03	1.20	2.30	2.56	3.34	2.43	2.29
Other Income / (Expense), net	-0.40	3.38	-0.39	-1.52	3.46	-5.48	5.92	0.30	-5.09	2.95
Income Tax Expense	6.56	7.29	6.75	6.38	14	4.67	4.13	12	7.25	6.00
Basic Earnings per Share	$0.32	$0.71	$0.54	$0.54	$1.01	$0.76	$0.90	$0.77	$0.83	$0.79
Weighted Average Basic Shares Outstanding	48.90M	48.55M	48M	48.40M	48.70M	48.27M	48.21M	48.91M	48.62M	48.43M
Diluted Earnings per Share	$0.30	$0.64	$0.50	$0.49	$0.91	$0.70	$0.81	$0.73	$0.78	$0.74
Weighted Average Diluted Shares Outstanding	52.79M	52.43M	51.97M	53.10M	53.92M	53.00M	53.01M	52.05M	51.86M	52.06M
Weighted Average Basic & Diluted Shares Outstanding	48.33M	47.90M	48.27M	48.86M	47.91M	48.10M	48.90M	48.68M	48.08M	47.65M

This table details how cash moves in and out of Amphastar Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	14	-1.75	6.28	-4.90	21	-13	19	32	30	-12	7.31
Net Cash From Operating Activities	21	11	39	39	38	42	57	98	89	184	213
Net Cash From Continuing Operating Activities	21	11	39	39	38	42	57	98	89	184	213
Net Income / (Loss) Continuing Operations	-11	-2.79	9.82	3.65	-6.66	47	1.10	63	91	138	160
Consolidated Net Income / (Loss)	-11	-2.79	9.82	3.65	-6.66	47	1.10	63	91	138	160
Depreciation Expense	13	11	12	13	15	17	20	22	24	25	28
Amortization Expense	1.92	1.94	2.52	2.86	1.99	4.05	4.69	4.56	4.93	28	35
Non-Cash Adjustments To Reconcile Net Income	9.93	13	16	15	18	18	19	5.68	17	31	22
Changes in Operating Assets and Liabilities, net	7.38	-13	-2.30	5.00	10	-44	12	2.26	-48	-38	-32
Net Cash From Investing Activities	-40	-17	-40	-37	-42	-51	-36	-29	-33	-649	-125
Net Cash From Continuing Investing Activities	-40	-17	-40	-37	-42	-51	-36	-29	-33	-649	-125
Purchase of Property, Plant & Equipment	-20	-16	-21	-35	-47	-42	-34	-27	-24	-38	-41
Acquisitions	-18	-	-12	-	0.00	-	-	0.00	0.00	-506	-129
Purchase of Investments	-	-	-3.60	-5.65	-0.31	-8.82	-14	-17	-36	-145	-77
Sale of Property, Plant & Equipment	-	-	-	-	0.25	-	0.00	0.00	0.42	0.00	0.00
Sale and/or Maturity of Investments	-	-	3.08	3.65	0.09	0.00	12	19	28	39	126
Other Investing Activities, net	-0.92	-0.93	-5.13	-1.80	0.20	-0.16	-1.41	-2.61	-1.37	1.39	-4.12
Net Cash From Financing Activities	32	2.24	7.14	-7.72	25	-3.78	-2.25	-37	-26	454	-81
Net Cash From Continuing Financing Activities	32	2.24	7.14	-7.72	25	-3.78	-2.25	-37	-26	454	-81
Repayment of Debt	-54	-8.99	-15	-9.71	-5.71	-6.78	-8.40	-40	-2.19	-344	-9.08
Repurchase of Common Equity	-2.27	-9.87	-9.91	-31	-25	-22	-24	-29	-40	-58	-85
Issuance of Debt	52	6.79	10	19	8.78	3.57	7.52	70	0.00	845	18
Issuance of Common Equity	38	14	22	14	47	22	23	16	16	11	0.00
Other Financing Activities, net	-1.11	-	-	-	0.00	0.00	-0.11	-54	0.00	0.00	-4.85
Effect of Exchange Rate Changes	0.85	2.25	0.08	0.50	-0.27	-0.10	0.35	-0.22	-0.22	-0.28	-0.19
Cash Interest Paid	2.61	1.94	1.72	1.88	2.38	2.44	2.20	2.11	3.02	18	27
Cash Income Taxes Paid	0.44	0.15	3.40	4.88	0.34	5.72	3.41	8.10	44	49	40

This table details how cash moves in and out of Amphastar Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-8.91	-1.15	21	-26	120	-127	57	-12	2.50	-41
Net Cash From Operating Activities	20	15	40	55	64	24	55	69	60	29
Net Cash From Continuing Operating Activities	20	15	40	55	64	24	55	69	60	29
Net Income / (Loss) Continuing Operations	16	34	26	26	49	36	43	38	40	38
Consolidated Net Income / (Loss)	16	34	26	26	49	36	43	38	40	38
Depreciation Expense	6.20	6.20	6.25	5.87	6.44	6.65	6.82	6.96	7.22	7.26
Amortization Expense	1.37	1.16	1.20	4.34	12	10	9.28	9.63	7.96	8.13
Non-Cash Adjustments To Reconcile Net Income	3.64	3.48	7.09	10	2.05	11	3.29	5.94	12	1.24
Changes in Operating Assets and Liabilities, net	-6.71	-30	-0.20	8.48	-5.74	-40	-7.27	8.64	-7.33	-26
Net Cash From Investing Activities	-15	-0.23	-6.33	-509	-31	-103	15	-70	-35	-36
Net Cash From Continuing Investing Activities	-15	-0.23	-6.33	-509	-31	-103	15	-70	-35	-36
Purchase of Property, Plant & Equipment	-5.62	-6.31	-9.48	-9.05	-10	-9.44	-8.79	-6.04	-14	-12
Purchase of Investments	-19	-5.19	-11	-9.20	-33	-92	-23	-	-25	-29
Sale and/or Maturity of Investments	9.07	13	14	11	14	-0.18	47	66	5.26	7.48
Other Investing Activities, net	-0.15	-1.23	-0.35	-0.59	4.00	-1.67	-0.96	-0.64	-1.06	-1.47
Net Cash From Financing Activities	-14	-16	-14	428	87	-47	-14	-11	-23	-34
Net Cash From Continuing Financing Activities	-14	-16	-14	428	87	-47	-14	-11	-23	-34
Repayment of Debt	-0.84	-0.13	-0.97	-82	-211	-51	-0.35	-8.01	-0.63	-0.09
Repurchase of Common Equity	-14	-18	-8.02	-0.13	-50	-	0.00	-8.50	-35	-42
Issuance of Debt	-	-	0.00	500	345	-	4.08	-0.03	9.51	4.87
Other Financing Activities, net	-	-	-4.57	4.57	-	-	-17	5.82	3.26	3.39
Effect of Exchange Rate Changes	-0.10	0.02	0.02	-0.02	-0.04	-0.24	-0.10	-0.02	-0.06	-0.01
Cash Interest Paid	0.79	1.06	1.25	1.53	9.33	5.48	8.63	5.23	8.53	4.42
Cash Income Taxes Paid	11	9.28	0.34	0.99	0.81	47	0.35	17	12	11

This table presents Amphastar Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	389	390	428	451	514	587	631	672	742	1,513	1,577
Total Current Assets	198	176	184	188	220	255	280	318	378	490	534
Cash & Equivalents	68	66	72	66	86	74	93	126	156	144	152
Restricted Cash	1.50	1.29	1.39	4.16	4.16	4.16	4.07	2.44	2.44	2.44	2.44
Short-Term Investments	-	-	0.53	2.64	2.83	12	13	10	20	113	70
Accounts Receivable	23	33	27	36	52	45	66	79	89	115	136
Inventories, net	82	71	80	64	69	111	97	93	104	106	154
Prepaid Expenses	3.68	4.44	3.27	9.75	5.49	9.54	6.78	7.27	7.56	9.06	18
Other Current Assets	0.27	0.24	0.02	6.04	0.05	0.31	0.39	0.13	0.17	0.53	1.75
Plant, Property, & Equipment, net	138	142	153	181	210	234	260	244	238	283	297
Total Noncurrent Assets	53	72	91	83	83	98	91	109	125	741	746
Long-Term Investments	-	-	-	-	-	-	-	3.99	2.41	15	11
Noncurrent Note & Lease Receivables	-	-	-	-	-	0.89	0.61	0.35	0.75	0.56	0.38
Goodwill	43	40	50	45	42	41	41	39	37	613	591
Noncurrent Deferred & Refundable Income Taxes	6.93	27	31	29	31	26	25	22	39	53	71
Other Noncurrent Operating Assets	3.59	4.70	9.39	8.66	9.92	30	25	44	46	58	73
Total Liabilities & Shareholders' Equity	389	390	428	451	514	587	631	672	742	1,513	1,577
Total Liabilities	108	95	98	117	149	159	183	226	213	873	845
Total Current Liabilities	63	60	61	67	107	90	112	104	95	225	174
Short-Term Debt	7.59	11	5.37	6.31	18	7.74	12	2.20	3.05	0.44	0.23
Accounts Payable	10	14	48	58	87	77	96	90	84	93	157
Accrued Expenses	13	17	-	-	-	-	-	-	0.00	126	0.00
Current Deferred & Payable Income Tax Liabilities	4.32	3.08	7.71	3.33	1.19	2.04	1.08	9.08	4.57	1.61	9.66
Other Current Liabilities	1.92	1.86	-	-	-	3.18	3.36	2.98	3.00	3.91	6.80
Total Noncurrent Liabilities	45	35	38	50	42	69	70	122	118	648	671
Long-Term Debt	36	30	32	41	32	39	34	75	73	590	602
Noncurrent Deferred Revenue	2.48	1.84	0.85	0.88	0.42	3.43	4.71	6.53	7.23	6.07	6.96
Other Noncurrent Operating Liabilities	0.49	2.67	3.21	7.06	8.94	26	31	40	38	52	63
Total Equity & Noncontrolling Interests	282	296	329	334	364	428	449	446	529	639	732
Total Preferred & Common Equity	282	296	329	334	332	381	402	446	529	639	732
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	282	296	329	334	332	381	402	446	529	639	732
Common Stock	221	248	283	314	344	367	410	422	455	486	505
Retained Earnings	63	60	71	73	67	116	118	180	272	409	569
Treasury Stock	-0.35	-10	-20	-51	-75	-98	-122	-150	-190	-247	-333
Accumulated Other Comprehensive Income / (Loss)	-1.65	-2.48	-4.70	-2.10	-4.01	-4.69	-3.72	-6.77	-8.62	-8.48	-9.18

This table presents Amphastar Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	727	774	1,378	1,545	1,574	1,492	1,545
Total Current Assets	384	408	385	543	555	483	546
Cash & Equivalents	157	177	149	267	201	190	192
Restricted Cash	2.44	2.44	4.89	6.46	2.44	2.44	2.44
Short-Term Investments	27	16	15	33	88	28	58
Accounts Receivable	77	101	105	119	138	131	140
Inventories, net	103	104	105	110	115	122	130
Prepaid Expenses	5.99	7.33	5.87	6.20	8.70	7.95	18
Other Current Assets	11	0.73	1.33	1.51	0.78	0.67	5.35
Plant, Property, & Equipment, net	233	243	279	281	289	288	295
Total Noncurrent Assets	110	123	715	721	731	721	704
Long-Term Investments	2.69	1.76	1.46	2.00	15	9.94	0.00
Noncurrent Note & Lease Receivables	0.60	0.71	0.66	0.61	0.52	0.47	0.43
Goodwill	37	37	626	619	607	601	595
Noncurrent Deferred & Refundable Income Taxes	22	39	41	41	53	53	53
Other Noncurrent Operating Assets	47	44	47	58	55	56	55
Total Liabilities & Shareholders' Equity	727	774	1,378	1,545	1,574	1,492	1,545
Total Liabilities	222	225	789	949	902	778	818
Total Current Liabilities	102	106	251	258	255	137	159
Short-Term Debt	1.68	2.17	13	0.43	0.43	0.25	0.25
Accounts Payable	96	89	218	223	117	131	153
Accrued Expenses	-	-	-	-	128	0.00	0.00
Current Deferred & Payable Income Tax Liabilities	1.53	12	18	31	5.86	1.51	1.28
Other Current Liabilities	3.18	2.99	3.13	3.72	3.94	4.00	4.21
Total Noncurrent Liabilities	119	119	538	692	647	641	658
Long-Term Debt	74	73	488	638	594	587	596
Noncurrent Deferred Revenue	6.53	7.23	7.23	7.23	6.07	6.07	6.07
Other Noncurrent Operating Liabilities	39	39	42	46	47	48	56
Total Equity & Noncontrolling Interests	505	549	589	595	672	713	728
Total Preferred & Common Equity	505	549	589	595	672	713	728
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	505	549	589	595	672	713	728
Common Stock	449	457	471	478	476	488	496
Retained Earnings	238	298	324	373	452	490	531
Treasury Stock	-171	-198	-197	-247	-247	-256	-291
Accumulated Other Comprehensive Income / (Loss)	-9.93	-8.27	-8.32	-8.41	-8.77	-8.83	-8.82

This table displays calculated financial ratios and metrics derived from Amphastar Pharmaceuticals' official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-8.37%	19.51%	1.45%	-5.87%	22.69%	9.40%	8.53%	25.13%	13.98%	29.14%	13.59%
EBITDA Growth	-110.73%	206.78%	744.44%	-41.92%	-63.48%	1,161.89%	-63.28%	276.24%	30.70%	69.46%	10.76%
EBIT Growth	-198.80%	45.50%	258.73%	-89.27%	-714.48%	685.36%	-92.64%	1,832.32%	38.07%	65.62%	8.51%
NOPAT Growth	-204.53%	61.64%	313.74%	-135.90%	-62.90%	99.50%	8,705.51%	1,935.60%	62.55%	87.05%	8.05%
Net Income Growth	-190.20%	73.95%	452.35%	-62.86%	-282.62%	798.27%	-97.64%	5,670.37%	44.37%	50.51%	15.98%
EPS Growth	-180.65%	76.00%	450.00%	-61.90%	-250.00%	916.67%	-96.94%	4,066.67%	39.20%	49.43%	17.69%
Operating Cash Flow Growth	-20.70%	-49.26%	261.01%	1.68%	-2.60%	9.35%	37.12%	71.12%	-8.99%	105.76%	16.28%
Free Cash Flow Firm Growth	81.54%	55.42%	26.38%	-48.51%	3.74%	-240.46%	103.52%	2,513.10%	-29.93%	-999.14%	107.88%
Invested Capital Growth	11.99%	5.08%	8.71%	5.40%	4.13%	19.89%	0.09%	-1.58%	11.74%	125.27%	15.09%
Revenue Q/Q Growth	0.00%	9.13%	-4.98%	-1.29%	11.04%	-1.92%	3.72%	6.05%	2.92%	7.16%	1.16%
EBITDA Q/Q Growth	0.00%	127.67%	-32.98%	27.35%	50.83%	2.23%	-25.62%	50.49%	11.37%	7.25%	-0.63%
EBIT Q/Q Growth	0.00%	63.59%	-50.08%	181.89%	14.88%	0.86%	-72.15%	79.99%	13.69%	3.92%	-0.19%
NOPAT Q/Q Growth	0.00%	75.62%	-57.09%	-26.64%	28.64%	-102.16%	-45.60%	44.70%	18.48%	11.03%	-4.68%
Net Income Q/Q Growth	0.00%	78.30%	-52.80%	844.29%	13.45%	-2.03%	-85.65%	67.69%	18.33%	1.67%	1.14%
EPS Q/Q Growth	0.00%	79.31%	-53.33%	900.00%	14.29%	-6.67%	-76.92%	73.61%	16.00%	2.36%	1.32%
Operating Cash Flow Q/Q Growth	65.18%	-45.83%	38.50%	-9.76%	-0.65%	-8.47%	24.42%	31.63%	-22.04%	4.94%	2.48%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	35.37%	-219.01%	4.71%	-9.98%	118.53%	37.09%	-38.89%	4.80%	-18.44%
Invested Capital Q/Q Growth	0.00%	4.39%	-3.18%	0.98%	1.42%	2.36%	-1.96%	-1.89%	8.24%	3.19%	2.58%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	24.35%	30.75%	40.83%	37.68%	36.31%	40.92%	40.97%	45.63%	49.87%	54.49%	51.08%
EBITDA Margin	-1.58%	1.42%	11.78%	7.27%	2.16%	24.96%	8.45%	25.40%	29.12%	38.21%	37.26%
Operating Margin	-8.54%	-2.74%	6.03%	-0.53%	-2.93%	-0.01%	3.13%	15.96%	21.54%	30.57%	28.06%
EBIT Margin	-8.45%	-3.85%	6.03%	0.69%	-3.44%	18.41%	1.25%	19.28%	23.36%	29.96%	28.62%
Profit (Net Income) Margin	-5.08%	-1.11%	3.85%	1.52%	-2.26%	14.43%	0.31%	14.46%	18.31%	21.34%	21.79%
Tax Burden Percent	58.95%	26.89%	67.12%	291.99%	67.10%	77.21%	23.66%	75.23%	78.75%	80.27%	84.06%
Interest Burden Percent	102.06%	106.93%	95.10%	75.70%	97.90%	101.48%	106.13%	99.66%	99.55%	88.76%	90.58%
Effective Tax Rate	0.00%	0.00%	32.88%	-191.99%	0.00%	22.79%	76.34%	24.52%	20.23%	18.58%	15.64%
Return on Invested Capital (ROIC)	-5.19%	-1.84%	3.67%	-1.23%	-1.92%	-0.01%	0.67%	13.79%	21.35%	23.26%	16.87%
ROIC Less NNEP Spread (ROIC-NNEP)	-13.00%	-9.71%	5.27%	-25.04%	-0.09%	-108.88%	3.50%	-2.52%	14.75%	1.59%	12.83%
Return on Net Nonoperating Assets (RNNOA)	1.18%	0.87%	-0.53%	2.33%	0.01%	11.75%	-0.42%	0.36%	-2.59%	0.29%	6.38%
Return on Equity (ROE)	-4.01%	-0.97%	3.14%	1.10%	-1.91%	11.75%	0.25%	14.16%	18.76%	23.55%	23.26%
Cash Return on Invested Capital (CROIC)	-16.50%	-6.79%	-4.67%	-6.49%	-5.96%	-18.10%	0.58%	15.38%	10.26%	-53.76%	2.84%
Operating Return on Assets (OROA)	-4.88%	-2.49%	3.76%	0.38%	-2.10%	10.79%	0.72%	12.96%	16.49%	17.12%	13.56%
Return on Assets (ROA)	-2.94%	-0.72%	2.40%	0.83%	-1.38%	8.45%	0.18%	9.72%	12.93%	12.20%	10.32%
Return on Common Equity (ROCE)	-4.01%	-0.97%	3.14%	1.10%	-1.82%	10.59%	0.22%	13.42%	18.76%	23.55%	23.26%
Return on Equity Simple (ROE_SIMPLE)	-3.80%	-0.94%	2.98%	1.09%	-2.00%	12.19%	0.27%	14.21%	17.29%	21.51%	21.78%
Net Operating Profit after Tax (NOPAT)	-13	-4.83	10	-3.71	-6.04	-0.03	2.59	53	86	160	173
NOPAT Margin	-5.98%	-1.92%	4.04%	-1.54%	-2.05%	-0.01%	0.74%	12.05%	17.18%	24.89%	23.68%
Net Nonoperating Expense Percent (NNEP)	7.81%	7.87%	-1.59%	23.80%	-1.83%	108.87%	-2.83%	16.31%	6.60%	21.67%	4.04%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	14.18%	13.05%	12.99%
Cost of Revenue to Revenue	75.65%	69.25%	59.17%	62.32%	63.69%	59.08%	59.03%	54.37%	50.13%	45.51%	48.92%
SG&A Expenses to Revenue	16.54%	16.50%	16.39%	18.51%	16.93%	15.60%	14.40%	11.75%	9.03%	8.00%	7.75%
R&D to Revenue	13.72%	14.82%	16.27%	18.11%	19.54%	21.36%	19.22%	13.92%	14.98%	11.44%	10.10%
Operating Expenses to Revenue	32.90%	33.49%	34.81%	38.21%	39.23%	40.94%	37.84%	29.66%	28.33%	23.92%	23.01%
Earnings before Interest and Taxes (EBIT)	-18	-9.69	15	1.65	-10	59	4.37	84	117	193	209
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-3.33	3.56	30	17	6.38	80	30	111	145	246	273
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	2.65	2.76	2.37	2.37	2.50	2.56	4.63	2.44
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	3.07	3.16	2.66	2.64	2.74	2.76	113.41	12.60
Price to Revenue (P/Rev)	0.00	0.00	0.00	3.68	3.11	2.81	2.73	2.55	2.71	4.60	2.44
Price to Earnings (P/E)	0.00	0.00	0.00	242.55	0.00	18.50	680.90	17.94	14.82	21.54	11.19
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.41%	0.00%	5.41%	0.15%	5.57%	6.75%	4.64%	8.94%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	2.79	2.82	2.36	2.43	2.76	2.95	3.43	1.96
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	3.58	3.08	2.82	2.68	2.39	2.50	5.09	2.94
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	49.22	142.10	11.30	31.76	9.43	8.60	13.32	7.89
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	520.82	0.00	15.32	214.81	12.42	10.72	16.98	10.27
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	362.15	19.87	14.57	20.44	12.42
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	21.92	23.73	21.77	16.39	10.70	14.01	17.87	10.09
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	416.84	17.82	30.31	0.00	73.71
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.16	0.14	0.11	0.14	0.14	0.11	0.10	0.17	0.14	0.92	0.82
Long-Term Debt to Equity	0.13	0.10	0.10	0.12	0.09	0.09	0.08	0.17	0.14	0.92	0.82
Financial Leverage	-0.09	-0.09	-0.10	-0.09	-0.10	-0.11	-0.12	-0.14	-0.18	0.18	0.50
Leverage Ratio	1.37	1.35	1.31	1.33	1.38	1.39	1.39	1.46	1.45	1.93	2.25
Compound Leverage Factor	1.39	1.44	1.24	1.00	1.35	1.41	1.48	1.45	1.44	1.71	2.04
Debt to Total Capital	13.42%	12.21%	10.28%	12.38%	12.11%	9.93%	9.38%	14.73%	12.55%	47.99%	45.11%
Short-Term Debt to Total Capital	2.33%	3.25%	1.46%	1.66%	4.40%	1.63%	2.48%	0.42%	0.50%	0.04%	0.02%
Long-Term Debt to Total Capital	11.09%	8.96%	8.82%	10.72%	7.71%	8.30%	6.90%	14.31%	12.05%	47.96%	45.09%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	7.70%	9.73%	9.37%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	86.58%	87.79%	89.72%	87.62%	80.19%	80.34%	81.25%	85.27%	87.45%	52.01%	54.89%
Debt to EBITDA	-13.11	11.54	1.25	2.70	7.87	0.59	1.57	0.69	0.52	2.40	2.21
Net Debt to EBITDA	7.69	-7.38	-1.22	-1.44	-6.76	-0.53	-2.14	-0.59	-0.72	1.28	1.34
Long-Term Debt to EBITDA	-10.83	8.47	1.08	2.34	5.02	0.49	1.16	0.67	0.50	2.39	2.21
Debt to NOPAT	-3.47	-8.51	3.66	-12.73	-8.32	-1,565.23	17.92	1.46	0.89	3.68	3.47
Net Debt to NOPAT	2.04	5.44	-3.54	6.81	7.14	1,407.33	-24.40	-1.25	-1.22	1.97	2.12
Long-Term Debt to NOPAT	-2.87	-6.25	3.14	-11.02	-5.30	-1,308.17	13.19	1.42	0.85	3.68	3.47
Altman Z-Score	0.00	0.00	0.00	5.61	4.65	4.91	4.30	4.78	5.97	3.47	2.95
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	4.57%	9.86%	10.57%	5.19%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.16	2.93	3.04	2.79	2.06	2.84	2.49	3.06	3.99	2.17	3.07
Quick Ratio	1.45	1.66	1.64	1.55	1.32	1.45	1.53	2.08	2.79	1.65	2.06
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-40	-18	-13	-20	-19	-64	2.25	59	41	-371	29
Operating Cash Flow to CapEx	102.70%	66.77%	180.34%	111.71%	82.02%	100.50%	169.15%	356.91%	377.68%	480.80%	519.93%
Free Cash Flow to Firm to Interest Expense	-65.71	-18.08	-12.83	-23.62	-77.27	-537.22	6.02	66.48	22.33	-13.65	0.96
Operating Cash Flow to Interest Expense	34.57	10.82	37.66	47.47	157.16	350.94	153.12	110.73	48.31	6.76	7.03
Operating Cash Flow Less CapEx to Interest Expense	0.91	-5.39	16.78	4.98	-34.45	1.74	62.60	79.70	35.52	5.35	5.68
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.58	0.65	0.62	0.55	0.61	0.59	0.57	0.67	0.71	0.57	0.47
Accounts Receivable Turnover	8.87	8.97	8.50	7.65	6.68	6.61	6.28	6.05	5.95	6.33	5.83
Inventory Turnover	2.09	2.28	2.01	2.09	2.82	2.12	1.99	2.51	2.55	2.80	2.76
Fixed Asset Turnover	1.65	1.79	1.73	1.44	1.51	1.45	1.42	1.74	2.07	2.47	2.52
Accounts Payable Turnover	10.43	14.49	4.92	2.85	2.59	2.32	2.39	2.57	2.88	3.30	2.86
Days Sales Outstanding (DSO)	41.13	40.69	42.92	47.70	54.60	55.22	58.10	60.37	61.30	57.70	62.64
Days Inventory Outstanding (DIO)	174.53	160.31	181.84	174.81	129.26	172.33	183.23	145.40	143.29	130.32	132.28
Days Payable Outstanding (DPO)	35.01	25.18	74.25	128.16	140.97	157.62	152.50	141.88	126.80	110.52	127.62
Cash Conversion Cycle (CCC)	180.65	175.83	150.51	94.35	42.89	69.94	88.84	63.89	77.79	77.50	67.30
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	256	269	293	309	321	385	385	379	424	955	1,099
Invested Capital Turnover	0.87	0.96	0.91	0.80	0.94	0.91	0.91	1.14	1.24	0.93	0.71
Increase / (Decrease) in Invested Capital	27	13	23	16	13	64	0.34	-6.08	45	531	144
Enterprise Value (EV)	0.00	0.00	0.00	859	906	909	938	1,048	1,250	3,279	2,152
Market Capitalization	0.00	0.00	0.00	885	917	905	955	1,114	1,354	2,963	1,785
Book Value per Share	$6.72	$6.57	$7.26	$7.26	$7.21	$8.12	$8.47	$9.31	$10.94	$13.35	$15.23
Tangible Book Value per Share	$5.70	$5.69	$6.15	$6.28	$6.29	$7.25	$7.61	$8.50	$10.17	$0.55	$2.95
Total Capital	326	337	367	381	415	475	495	523	605	1,229	1,334
Total Debt	44	41	38	47	50	47	46	77	76	590	602
Total Long-Term Debt	36	30	32	41	32	39	34	75	73	590	602
Net Debt	-26	-26	-37	-25	-43	-42	-63	-66	-105	316	367
Capital Expenditures (CapEx)	20	16	21	35	47	42	34	27	24	38	41
Debt-free, Cash-free Net Working Capital (DFCFNWC)	74	60	55	55	38	83	70	77	108	5.39	136
Debt-free Net Working Capital (DFNWC)	143	127	129	127	132	173	180	217	287	265	361
Net Working Capital (NWC)	135	116	123	121	114	165	167	214	283	264	360
Net Nonoperating Expense (NNE)	-1.89	-2.04	0.50	-7.35	0.62	-47	1.49	-11	-5.64	23	14
Net Nonoperating Obligations (NNO)	-26	-26	-37	-25	-43	-42	-63	-66	-105	316	367
Total Depreciation and Amortization (D&A)	14	13	15	16	17	21	25	27	29	53	63
Debt-free, Cash-free Net Working Capital to Revenue	35.01%	23.68%	21.39%	22.70%	13.04%	25.89%	20.03%	17.68%	21.71%	0.84%	18.64%
Debt-free Net Working Capital to Revenue	67.94%	50.46%	50.49%	52.84%	44.71%	53.66%	51.38%	49.46%	57.42%	41.07%	49.26%
Net Working Capital to Revenue	64.34%	46.11%	48.39%	50.21%	38.52%	51.26%	47.87%	48.95%	56.81%	41.00%	49.23%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.25)	($0.06)	$0.23	$0.10	($0.12)	$1.04	$0.03	$1.30	$1.88	$2.85	$3.29
Adjusted Weighted Average Basic Shares Outstanding	41.96M	44.96M	45.38M	46.11M	46.40M	46.98M	47.04M	47.78M	48.55M	48.27M	48.43M
Adjusted Diluted Earnings per Share	($0.25)	($0.06)	$0.22	$0.09	($0.12)	$0.98	$0.03	$1.25	$1.74	$2.60	$3.06
Adjusted Weighted Average Diluted Shares Outstanding	41.96M	44.96M	47.50M	48.37M	46.40M	49.91M	49.12M	49.78M	52.43M	53.00M	52.06M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	44.56M	44.91M	45.91M	46.35M	46.79M	46.24M	47.43M	48.15M	47.90M	48.10M	47.65M
Normalized Net Operating Profit after Tax (NOPAT)	-13	-4.83	10	-2.74	-6.04	-0.03	7.67	53	86	160	173
Normalized NOPAT Margin	-5.98%	-1.92%	4.04%	-1.14%	-2.05%	-0.01%	2.19%	12.05%	17.18%	24.89%	23.68%
Pre Tax Income Margin	-8.62%	-4.12%	5.73%	0.52%	-3.37%	18.68%	1.33%	19.22%	23.26%	26.59%	25.93%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-29.20	-9.82	15.02	2.00	-41.72	498.74	11.68	95.39	63.14	7.11	6.90
NOPAT to Interest Expense	-20.67	-4.89	10.08	-4.49	-24.84	-0.25	6.93	59.61	46.45	5.91	5.71
EBIT Less CapEx to Interest Expense	-62.86	-26.03	-5.86	-40.50	-233.34	149.54	-78.84	64.37	50.35	5.70	5.55
NOPAT Less CapEx to Interest Expense	-54.33	-21.10	-10.80	-46.98	-216.46	-349.45	-83.59	28.58	33.66	4.50	4.36
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-21.17%	-353.96%	100.90%	843.08%	-376.08%	47.93%	2,226.53%	45.61%	43.67%	42.27%	53.57%

This table displays calculated financial ratios and metrics derived from Amphastar Pharmaceuticals' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	7.07%	11.69%	16.33%	18.02%	50.30%	31.91%	22.72%	25.17%	5.90%	4.73%
EBITDA Growth	-31.75%	44.00%	12.49%	50.27%	212.32%	34.26%	72.90%	58.14%	-29.29%	-2.63%
EBIT Growth	-39.97%	51.65%	13.13%	51.72%	233.48%	17.69%	63.21%	56.91%	-31.76%	-0.83%
NOPAT Growth	-19.07%	74.71%	43.76%	57.48%	243.70%	53.72%	64.26%	40.34%	-14.63%	-18.58%
Net Income Growth	-48.73%	71.62%	7.34%	50.61%	210.08%	6.65%	65.86%	45.26%	-17.86%	4.97%
EPS Growth	-49.15%	60.00%	6.38%	48.48%	203.33%	9.38%	62.00%	48.98%	-14.29%	5.71%
Operating Cash Flow Growth	693.11%	-62.35%	-20.45%	1,851.08%	215.75%	56.73%	36.92%	25.83%	-6.80%	21.62%
Free Cash Flow Firm Growth	-56.89%	-155.95%	-210.07%	-202,747.37%	-4,225.19%	-3,511.87%	-1,238.36%	78.68%	79.54%	78.24%
Invested Capital Growth	1.27%	11.74%	17.41%	138.38%	136.30%	125.27%	124.99%	16.22%	15.78%	15.09%
Revenue Q/Q Growth	-2.70%	12.40%	3.70%	4.06%	23.91%	-1.36%	-3.52%	6.14%	4.84%	-2.45%
EBITDA Q/Q Growth	0.20%	59.75%	-16.61%	12.58%	108.25%	-31.33%	7.40%	2.96%	-6.89%	-5.43%
EBIT Q/Q Growth	-2.09%	80.49%	-19.81%	7.07%	115.20%	-36.30%	11.20%	2.94%	-6.41%	-7.43%
NOPAT Q/Q Growth	-12.64%	88.94%	-14.25%	11.27%	90.66%	-15.50%	-8.37%	-4.94%	15.98%	-19.40%
Net Income Q/Q Growth	-8.49%	113.64%	-23.24%	0.35%	88.42%	-26.52%	19.38%	-12.11%	6.54%	-6.10%
EPS Q/Q Growth	-9.09%	113.33%	-21.88%	-2.00%	85.71%	-23.08%	15.71%	-9.88%	6.85%	-5.13%
Operating Cash Flow Q/Q Growth	623.80%	-25.27%	165.22%	36.01%	17.13%	-62.91%	131.69%	24.99%	-13.24%	-51.60%
Free Cash Flow Firm Q/Q Growth	4,747.04%	-215.66%	-173.26%	-1,281.19%	5.50%	-1.26%	-1.25%	78.00%	9.29%	-7.66%
Invested Capital Q/Q Growth	1.37%	8.24%	0.61%	115.92%	0.49%	3.19%	0.49%	11.53%	0.11%	2.58%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	48.71%	52.71%	52.73%	49.92%	60.04%	53.98%	52.43%	52.18%	53.31%	46.45%
EBITDA Margin	25.31%	35.97%	28.92%	31.29%	52.58%	36.61%	40.75%	39.53%	35.11%	34.03%
Operating Margin	19.34%	28.02%	23.88%	25.32%	40.25%	30.31%	27.94%	30.27%	29.83%	24.20%
EBIT Margin	19.01%	30.52%	23.60%	24.28%	42.17%	27.23%	31.39%	30.44%	27.17%	25.79%
Profit (Net Income) Margin	13.21%	25.12%	18.59%	17.93%	27.26%	20.31%	25.13%	20.81%	21.14%	20.35%
Tax Burden Percent	70.25%	82.19%	77.55%	79.63%	77.35%	87.48%	90.19%	75.53%	84.79%	86.36%
Interest Burden Percent	98.97%	100.13%	101.59%	92.73%	83.58%	85.25%	88.77%	90.50%	91.78%	91.41%
Effective Tax Rate	29.03%	17.67%	20.11%	19.46%	22.04%	11.30%	8.62%	24.47%	15.21%	13.64%
Return on Invested Capital (ROIC)	17.10%	28.66%	25.05%	16.88%	28.65%	25.13%	24.91%	16.37%	18.33%	14.90%
ROIC Less NNEP Spread (ROIC-NNEP)	17.88%	25.42%	25.62%	13.59%	21.79%	14.02%	24.07%	15.28%	15.98%	14.60%
Return on Net Nonoperating Assets (RNNOA)	-3.00%	-4.46%	-5.94%	2.73%	4.29%	2.53%	3.26%	8.08%	8.14%	7.26%
Return on Equity (ROE)	14.10%	24.20%	19.11%	19.61%	32.95%	27.66%	28.17%	24.45%	26.47%	22.16%
Cash Return on Invested Capital (CROIC)	17.33%	10.26%	7.64%	-65.85%	-59.12%	-53.76%	-51.19%	4.10%	3.59%	2.84%
Operating Return on Assets (OROA)	13.37%	21.55%	16.43%	12.50%	22.33%	15.56%	18.08%	15.12%	12.73%	12.21%
Return on Assets (ROA)	9.30%	17.73%	12.94%	9.23%	14.43%	11.61%	14.47%	10.34%	9.90%	9.64%
Return on Common Equity (ROCE)	14.10%	24.20%	19.11%	19.61%	32.95%	27.66%	28.17%	24.45%	26.47%	22.16%
Return on Equity Simple (ROE_SIMPLE)	15.29%	0.00%	16.98%	17.30%	22.73%	0.00%	23.01%	23.34%	21.67%	0.00%
Net Operating Profit after Tax (NOPAT)	16	31	27	30	57	48	44	42	48	39
NOPAT Margin	13.72%	23.07%	19.07%	20.39%	31.38%	26.88%	25.53%	22.87%	25.30%	20.90%
Net Nonoperating Expense Percent (NNEP)	-0.78%	3.24%	-0.57%	3.29%	6.86%	11.11%	0.84%	1.09%	2.36%	0.30%
Return On Investment Capital (ROIC_SIMPLE)	-	5.15%	-	-	-	3.89%	-	-	-	2.92%
Cost of Revenue to Revenue	51.29%	47.29%	47.27%	50.08%	39.96%	46.02%	47.57%	47.82%	46.69%	53.55%
SG&A Expenses to Revenue	9.98%	7.87%	9.63%	8.43%	7.01%	7.37%	9.12%	7.28%	7.75%	6.94%
R&D to Revenue	15.41%	12.77%	14.15%	11.56%	9.23%	11.46%	9.92%	9.68%	11.02%	9.73%
Operating Expenses to Revenue	29.37%	24.69%	28.86%	24.60%	19.79%	23.67%	24.49%	21.90%	23.48%	22.25%
Earnings before Interest and Taxes (EBIT)	23	41	33	35	76	48	54	56	52	48
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	30	49	40	46	95	65	70	72	67	63
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.73	2.56	3.27	4.71	3.78	4.63	3.14	2.74	3.25	2.44
Price to Tangible Book Value (P/TBV)	2.94	2.76	3.51	0.00	0.00	113.41	32.35	17.39	17.78	12.60
Price to Revenue (P/Rev)	2.84	2.71	3.46	5.13	3.74	4.60	3.12	2.74	3.26	2.44
Price to Earnings (P/E)	17.83	14.82	19.28	27.21	16.61	21.54	13.65	11.75	14.98	11.19
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	5.61%	6.75%	5.19%	3.67%	6.02%	4.64%	7.32%	8.51%	6.68%	8.94%
Enterprise Value to Invested Capital (EV/IC)	3.23	2.95	3.92	3.37	2.78	3.43	2.50	2.16	2.53	1.96
Enterprise Value to Revenue (EV/Rev)	2.61	2.50	3.23	5.74	4.29	5.09	3.55	3.24	3.74	2.94
Enterprise Value to EBITDA (EV/EBITDA)	9.69	8.60	11.18	18.82	11.22	13.32	8.70	7.65	9.86	7.89
Enterprise Value to EBIT (EV/EBIT)	12.33	10.72	13.90	23.45	13.87	16.98	11.21	9.88	12.89	10.27
Enterprise Value to NOPAT (EV/NOPAT)	17.46	14.57	17.92	29.82	17.84	20.44	13.46	12.17	14.88	12.42
Enterprise Value to Operating Cash Flow (EV/OCF)	11.05	14.01	21.25	23.73	14.74	17.87	12.09	10.88	13.00	10.09
Enterprise Value to Free Cash Flow (EV/FCFF)	18.73	30.31	55.48	0.00	0.00	0.00	0.00	56.70	75.59	73.71
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.15	0.14	0.14	0.85	1.07	0.92	0.88	0.82	0.82	0.82
Long-Term Debt to Equity	0.15	0.14	0.13	0.83	1.07	0.92	0.88	0.82	0.82	0.82
Financial Leverage	-0.17	-0.18	-0.23	0.20	0.20	0.18	0.14	0.53	0.51	0.50
Leverage Ratio	1.47	1.45	1.45	1.93	2.06	1.93	1.92	2.20	2.34	2.25
Compound Leverage Factor	1.46	1.45	1.47	1.79	1.73	1.65	1.71	1.99	2.14	2.06
Debt to Total Capital	13.03%	12.55%	12.03%	45.96%	51.76%	47.99%	46.92%	45.15%	45.06%	45.11%
Short-Term Debt to Total Capital	0.29%	0.50%	0.35%	1.18%	0.04%	0.04%	0.03%	0.02%	0.02%	0.02%
Long-Term Debt to Total Capital	12.74%	12.05%	11.69%	44.78%	51.73%	47.96%	46.89%	45.13%	45.04%	45.09%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	86.97%	87.45%	87.97%	54.04%	48.24%	52.01%	53.08%	54.85%	54.95%	54.89%
Debt to EBITDA	0.58	0.52	0.50	3.04	2.78	2.40	2.16	1.94	2.17	2.21
Net Debt to EBITDA	-0.87	-0.72	-0.81	2.01	1.44	1.28	1.04	1.18	1.25	1.34
Long-Term Debt to EBITDA	0.57	0.50	0.49	2.96	2.78	2.39	2.15	1.94	2.17	2.21
Debt to NOPAT	1.05	0.89	0.80	4.81	4.42	3.68	3.33	3.09	3.28	3.47
Net Debt to NOPAT	-1.57	-1.22	-1.31	3.18	2.29	1.97	1.61	1.88	1.89	2.12
Long-Term Debt to NOPAT	1.02	0.85	0.78	4.69	4.42	3.68	3.33	3.09	3.28	3.47
Altman Z-Score	5.43	5.64	6.61	3.03	2.53	3.16	2.58	2.85	3.09	2.61
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.76	3.99	3.86	1.53	2.11	2.17	2.18	3.52	3.43	3.07
Quick Ratio	2.56	2.79	2.78	1.07	1.62	1.65	1.68	2.55	2.45	2.06
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	12	-13	-37	-505	-477	-483	-489	-108	-98	-105
Operating Cash Flow to CapEx	362.35%	241.30%	426.11%	606.62%	631.16%	252.74%	628.81%	1,143.43%	434.73%	233.86%
Free Cash Flow to Firm to Interest Expense	20.44	-25.34	-91.85	-140.17	-34.82	-51.10	-56.81	-12.50	-14.58	-16.36
Operating Cash Flow to Interest Expense	36.00	28.84	101.46	15.25	4.70	2.52	6.42	8.03	8.95	4.52
Operating Cash Flow Less CapEx to Interest Expense	26.06	16.89	77.65	12.73	3.95	1.53	5.40	7.33	6.89	2.59
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.70	0.71	0.70	0.51	0.53	0.57	0.58	0.50	0.47	0.47
Accounts Receivable Turnover	6.25	5.95	5.97	5.83	6.13	6.33	5.66	6.04	5.60	5.83
Inventory Turnover	2.47	2.55	2.53	2.60	2.58	2.80	2.82	2.85	2.83	2.76
Fixed Asset Turnover	2.04	2.07	2.13	2.10	2.34	2.47	2.54	2.52	2.51	2.52
Accounts Payable Turnover	2.72	2.88	2.73	1.68	1.73	3.30	3.00	1.85	1.81	2.86
Days Sales Outstanding (DSO)	58.41	61.30	61.16	62.60	59.51	57.70	64.44	60.45	65.23	62.64
Days Inventory Outstanding (DIO)	148.00	143.29	144.10	140.24	141.42	130.32	129.50	128.24	128.90	132.28
Days Payable Outstanding (DPO)	134.34	126.80	133.88	217.38	211.25	110.52	121.49	197.00	201.70	127.62
Cash Conversion Cycle (CCC)	72.07	77.79	71.38	-14.54	-10.32	77.50	72.45	-8.31	-7.56	67.30
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	392	424	427	921	925	955	960	1,070	1,071	1,099
Invested Capital Turnover	1.25	1.24	1.31	0.83	0.91	0.93	0.98	0.72	0.72	0.71
Increase / (Decrease) in Invested Capital	4.92	45	63	535	534	531	533	149	146	144
Enterprise Value (EV)	1,264	1,250	1,674	3,106	2,577	3,279	2,399	2,313	2,706	2,152
Market Capitalization	1,377	1,354	1,796	2,774	2,247	2,963	2,112	1,956	2,362	1,785
Book Value per Share	$10.31	$10.94	$11.45	$12.21	$12.18	$13.35	$13.98	$14.59	$14.95	$15.23
Tangible Book Value per Share	$9.55	$10.17	$10.68	($0.75)	($0.50)	$0.55	$1.36	$2.30	$2.73	$2.95
Total Capital	581	605	624	1,090	1,234	1,229	1,267	1,300	1,324	1,334
Total Debt	76	76	75	501	639	590	594	587	597	602
Total Long-Term Debt	74	73	73	488	638	590	594	587	596	602
Net Debt	-114	-105	-122	332	330	316	287	357	344	367
Capital Expenditures (CapEx)	5.62	6.31	9.48	9.05	10	9.44	8.79	6.04	14	12
Debt-free, Cash-free Net Working Capital (DFCFNWC)	97	108	109	-22	-21	5.39	8.35	126	134	136
Debt-free Net Working Capital (DFNWC)	284	287	304	146	285	265	300	346	387	361
Net Working Capital (NWC)	282	283	302	133	285	264	300	346	387	360
Net Nonoperating Expense (NNE)	0.61	-2.77	0.68	3.59	7.44	12	0.70	3.76	7.94	1.02
Net Nonoperating Obligations (NNO)	-114	-105	-122	332	330	316	287	357	344	367
Total Depreciation and Amortization (D&A)	7.57	7.36	7.46	10	19	17	16	17	15	15
Debt-free, Cash-free Net Working Capital to Revenue	20.05%	21.71%	20.99%	-4.04%	-3.47%	0.84%	1.23%	17.63%	18.56%	18.64%
Debt-free Net Working Capital to Revenue	58.52%	57.42%	58.65%	27.03%	47.48%	41.07%	44.41%	48.52%	53.51%	49.26%
Net Working Capital to Revenue	58.17%	56.81%	58.24%	24.64%	47.40%	41.00%	44.35%	48.49%	53.48%	49.23%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.32	$0.71	$0.54	$0.54	$1.01	$0.76	$0.90	$0.77	$0.83	$0.79
Adjusted Weighted Average Basic Shares Outstanding	48.90M	48.55M	48M	48.40M	48.70M	48.27M	48.21M	48.91M	48.62M	48.43M
Adjusted Diluted Earnings per Share	$0.30	$0.64	$0.50	$0.49	$0.91	$0.70	$0.81	$0.73	$0.78	$0.74
Adjusted Weighted Average Diluted Shares Outstanding	52.79M	52.43M	51.97M	53.10M	53.92M	53.00M	53.01M	52.05M	51.86M	52.06M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	48.33M	47.90M	48.27M	48.86M	47.91M	48.10M	48.90M	48.68M	48.08M	47.65M
Normalized Net Operating Profit after Tax (NOPAT)	16	31	27	30	57	48	44	42	48	39
Normalized NOPAT Margin	13.72%	23.07%	19.07%	20.39%	31.38%	26.88%	25.53%	22.87%	25.30%	20.90%
Pre Tax Income Margin	18.81%	30.56%	23.97%	22.52%	35.25%	23.21%	27.86%	27.55%	24.94%	23.57%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	40.34	78.05	83.02	9.82	5.56	5.13	6.26	6.45	7.76	7.49
NOPAT to Interest Expense	29.13	58.99	67.11	8.25	4.14	5.06	5.09	4.84	7.22	6.07
EBIT Less CapEx to Interest Expense	30.40	66.09	59.21	7.31	4.81	4.13	5.24	5.75	5.70	5.55
NOPAT Less CapEx to Interest Expense	19.19	47.04	43.29	5.74	3.39	4.06	4.07	4.14	5.16	4.14
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	45.67%	43.67%	50.12%	39.93%	56.33%	42.27%	32.41%	35.13%	27.55%	53.57%

Frequently Asked Questions About Amphastar Pharmaceuticals' Financials

When does Amphastar Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Amphastar Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Amphastar Pharmaceuticals' net income changed over the last 10 years?

Amphastar Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of $159.52 million in 2024, falling from -$10.70 million in 2014. The previous period was $137.55 million in 2023.

What is Amphastar Pharmaceuticals's operating income?

Amphastar Pharmaceuticals's total operating income in 2024 was $205.42 million, based on the following breakdown:

Total Gross Profit: $373.86 million
Total Operating Expenses: $168.44 million

How has Amphastar Pharmaceuticals revenue changed over the last 10 years?

Over the last 10 years, Amphastar Pharmaceuticals' total revenue changed from $210.46 million in 2014 to $731.97 million in 2024, a change of 247.8%.

How much debt does Amphastar Pharmaceuticals have?

Amphastar Pharmaceuticals' total liabilities were at $845.17 million at the end of 2024, a 3.2% decrease from 2023, and a 686.1% increase since 2014.

How much cash does Amphastar Pharmaceuticals have?

In the past 10 years, Amphastar Pharmaceuticals' cash and equivalents has ranged from $65.59 million in 2017 to $156.10 million in 2022, and is currently $151.61 million as of their latest financial filing in 2024.

How has Amphastar Pharmaceuticals' book value per share changed over the last 10 years?

Over the last 10 years, Amphastar Pharmaceuticals' book value per share changed from 6.72 in 2014 to 15.23 in 2024, a change of 126.7%.

Remove Ads

Related Companies

This page (NASDAQ:AMPH) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amphastar Pharmaceuticals (AMPH) Financials

Frequently Asked Questions About Amphastar Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amphastar Pharmaceuticals (AMPH) Financials

Annual Income Statements for Amphastar Pharmaceuticals

Quarterly Income Statements for Amphastar Pharmaceuticals

Annual Cash Flow Statements for Amphastar Pharmaceuticals

Quarterly Cash Flow Statements for Amphastar Pharmaceuticals

Annual Balance Sheets for Amphastar Pharmaceuticals

Quarterly Balance Sheets for Amphastar Pharmaceuticals

Annual Metrics and Ratios for Amphastar Pharmaceuticals

Quarterly Metrics and Ratios for Amphastar Pharmaceuticals

Frequently Asked Questions About Amphastar Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools